While current treatment options like anti-inflammatory medications and anti-tumor necrosis factor (TNF) targeted therapies can be used to manage moderate to severe symptoms (Nakase et al., 2021; Salice et al., 2019), they often induce severe adverse effects, including liver and kidney impairment or an increased risk of infections (Ford and Peyrin-Biroulet, 2013; Luthra et al., 2015). The gene discussed is TNF; the disease is infection.